We evaluated the association between the CHRNA5-A3-B4 variants and smoking cessation outcomes in two independent smoking cessation trials. Both trials were conducted in African American light smokers (≤10 CPD) at the same community health center and the enrollment criteria were similar. These trials were focused on light smokers because 1) more than 50% of African American smokers are light smokers, and 2) little is known about the pharmacology and pharmacogenetics of smoking cessation treatments in this population.
